Frederic Chereau | Chief Executive OfficerLogicBio Therapeutics

Frederic Chereau currently serves as President and Chief Executive Officer of LogicBio Therapeutics. From 2014 to 2015, Mr. Chereau was President and Chief Operating Officer of aTyr Pharma (LIFE). During his tenure, the company advanced multiple programs to clinical stage and successfully completed private financing and an IPO. Prior to that, Mr. Chereau was Senior Vice President and Angioedema Franchise Lead at Shire (SHPG), where he defined and oversaw the execution of the global strategy for the franchise, positioning it as the leader on its market. From 2008 to 2012, as President and Chief Executive Officer of Pervasis Therapeutics, he led the company through key strategies leading up to the acquisition of the company by Shire. Before Pervasis, Mr. Chereau worked at Genzyme from 1999 to 2008, where he held roles with increasing responsibility, initially within Genzyme France and Genzyme Europe, and achieved the position of Vice President and General Manager of the Cardiovascular Business Unit at Genzyme Corporation. Prior to Genzyme, he started his career at Hemotech, where he held sales and marketing roles. Mr. Chereau serves as a member of the Comite Strategique d’Orientation at La Rochelle Business School. He holds a B.S. in Physics from Paris University, received his master’s degree in management from La Rochelle Business School in France, and received an MBA from INSEAD, Fontainebleau, France and Singapore.

Appearances:

Conference Day 2: Friday 17th May 2019 @ 09:00

Best strategies for implementing new methods across the field of clinical research, now and for the future

Optimisation of the delivery of gene editing technology

How to minimise off-target effects and mutations for the safe and effective delivery of gene editing technology

Discussion of ethical and regulatory challenges, current legislation, how to navigate ethical concerns in light of the growing scale of genome editing. Most recently the CRISPR babies that were born in 2018

Edward Rebar, has served as Senior Vice President and Chief Technology Officer since July 2018. Dr. Rebar joined Sangamo in 1998, and over the last 20 years has led the development of the Company's zinc finger protein technology platform. He has authored over 60 publications relating to the...

Derek is a 15-year veteran of the genome editing industry. As a protein engineer, he was an early developer of zinc finger technology and has spent most of his research career designing proteins for genome editing applications. He has a B.A. in biology from the University of Colorado at Boulder and ...

Frederic Chereau, Chief Executive Officer,LogicBio Therapeutics

Frederic Chereau currently serves as President and Chief Executive Officer of LogicBio Therapeutics. From 2014 to 2015, Mr. Chereau was President and Chief Operating Officer of aTyr Pharma (LIFE). During his tenure, the company advanced multiple programs to clinical stage and successfully completed ...

The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.